Pazaitou-Panayiotou Kalliopi, Kelesidis Theodore, Kelesidis Iosif, Kaprara Athina, Blakeman Jennifer, Vainas Iraklis, Mpousoulegas Aris, Williams Catherine J, Mantzoros Christos
Department of Endocrinology-Endocrine Oncology, Theagenio Cancer Hospital, Thessaloniki, Greece.
Eur J Endocrinol. 2007 Feb;156(2):187-94. doi: 10.1530/EJE-06-0611.
Several components of the GH and IGF systems have been implicated in the development of malignancies. All components of these hormonal systems have never been jointly evaluated in female breast cancer, and previous studies have not examined the role of IGF-binding proteins (IGFBP-4, IGFBP-6) or GH-binding protein (GHBP).
Hospital-based case-control study.
In this sample of primarily postmenopausal women, we obtained serum measures of IGF-I, IGF-II, and binding proteins IGFBP-1, IGFBP-3, IGFBP-4, IGFBP-6, as well as GHBP, insulin, and leptin from 74 breast cancer cases and 76 control subjects.
In crude analyses, we found lower age-standardized mean IGF-I, IGFBP-3, IGFBP-4, IGFBP-6, and higher IGFBP-1 and GHBP in breast cancer cases when compared with controls. Multivariate models mutually adjusted for other GH-IGF system components and classical breast cancer risk factors demonstrated an inverse association between IGFBP-3 and risk of breast cancer (odds ratio (OR) = 0.2, P < 0.01) and a direct association between GHBP and disease risk (OR = 3.3, P < 0.01). No significant associations were detected in multivariate analyses among IGF-I, IGF-II or IGFBP-1, IGFBP-4, IGFBP-6 with risk of breast cancer, indicating that these factors may not have effects independent of and/or comparable with IGFBP-3 and GHBP.
These results support a protective role of IGFBP-3 and demonstrate for the first time an increased risk of breast cancer with higher GHBP, after accounting for variation in IGFs, IGFBPs, and classical breast cancer risk factors.
生长激素(GH)和胰岛素样生长因子(IGF)系统的多个成分与恶性肿瘤的发生有关。这些激素系统的所有成分从未在女性乳腺癌中进行过联合评估,并且先前的研究未考察胰岛素样生长因子结合蛋白(IGFBP - 4、IGFBP - 6)或生长激素结合蛋白(GHBP)的作用。
基于医院的病例对照研究。
在这个主要为绝经后女性的样本中,我们从74例乳腺癌病例和76名对照受试者中获取了血清中IGF - I、IGF - II、结合蛋白IGFBP - 1、IGFBP - 3、IGFBP - 4、IGFBP - 6以及GHBP、胰岛素和瘦素的测量值。
在粗分析中,我们发现与对照组相比,乳腺癌病例中年龄标准化的平均IGF - I、IGFBP - 3、IGFBP - 4、IGFBP - 6较低,而IGFBP - 1和GHBP较高。在对其他GH - IGF系统成分和经典乳腺癌危险因素进行相互调整的多变量模型中,显示IGFBP - 3与乳腺癌风险呈负相关(比值比(OR)= 0.2,P < 0.01),GHBP与疾病风险呈正相关(OR = 3.3,P < 0.01)。在多变量分析中,未检测到IGF - I、IGF - II或IGFBP - 1、IGFBP - 4、IGFBP - 6与乳腺癌风险之间存在显著关联,这表明这些因素可能没有独立于IGFBP - 3和GHBP的作用,也没有与之相当的作用。
这些结果支持IGFBP - 3的保护作用,并首次证明在考虑了IGF、IGFBP和经典乳腺癌危险因素的变异后,GHBP升高会增加乳腺癌风险。